Zobrazeno 1 - 8
of 8
pro vyhledávání: '"M G Franken"'
Autor:
R J S D Heine, F W Thielen, R H J Mathijssen, R W F van Leeuwen, M G Franken, C A Uyl-de Groot
Publikováno v:
PLoS ONE, Vol 19, Iss 2, p e0293264 (2024)
BackgroundExpanding the indication of already approved immuno-oncology drugs presents treatment opportunities for patients but also strains healthcare systems. Cost-based pricing models are discussed as a possibility for cost containment. This study
Externí odkaz:
https://doaj.org/article/824ea4703e6e4053acd4440678800be2
Autor:
E. E. A. P. Mulder, K. de Joode, S. Litière, A. J. ten Tije, K. P. M. Suijkerbuijk, M. J. Boers-Sonderen, G. A. P. Hospers, J. W. B. de Groot, A. J. M. van den Eertwegh, M. J. B. Aarts, D. Piersma, R. S. van Rijn, E. Kapiteijn, G. Vreugdenhil, F. W. P. J. van den Berkmortel, E. Oomen-de Hoop, M. G. Franken, B. Ryll, P. Rutkowski, S. Sleijfer, J. B. A. G. Haanen, A. A. M. van der Veldt
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-9 (2021)
Abstract Background The introduction of programmed cell death protein 1 (PD-1) blockers (i.e. nivolumab and pembrolizumab) has significantly improved the prognosis of patients with advanced melanoma. However, the long treatment duration (i.e. two yea
Externí odkaz:
https://doaj.org/article/1258e8cfb799432884b62bfb054d74e9
Autor:
J.J.M. van der Hoeven, Michel W.J.M. Wouters, A.C.J. van Akkooi, B. Leeneman, A.J. ten Tije, M. G. Franken, G. Vreugdenhil, C.A. Uyl-de Groot, R van Rijn, K. H. Herbschleb, D Piersma, J.W.B. de Groot, Geke A. P. Hospers, Maureen J.B. Aarts, F.W.P.J. van den Berkmortel, A.J.M. van den Eertwegh, Karijn P M Suijkerbuijk, A.A.M. Van der Veldt, J.B.A.G. Haanen, Ellen Kapiteijn
Publikováno v:
Value in Health. 22:S534
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::93228616dcea34d466f83ec581dfc315
https://doi.org/10.1016/j.jval.2019.09.689
https://doi.org/10.1016/j.jval.2019.09.689
Autor:
C.A. Uyl-de Groot, Geke A. P. Hospers, Michel W.J.M. Wouters, Maureen J.B. Aarts, Ellen Kapiteijn, A.C.J. van Akkooi, Karijn P M Suijkerbuijk, R van Rijn, J.B.A.G. Haanen, Zeijl M. Van, A.J. ten Tije, B. Leeneman, M. G. Franken, A.A.M. Van der Veldt, J.J.M. van der Hoeven, F.W.P.J. van den Berkmortel, A.J.M. van den Eertwegh, G. Vreugdenhil, K. H. Herbschleb, Djura Piersma, J.W.B. de Groot
Publikováno v:
Value in Health. 22:S535
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::191f97d25653da6332b1d729264796d9
https://doi.org/10.1016/j.jval.2019.09.693
https://doi.org/10.1016/j.jval.2019.09.693
Autor:
G. Vreugdenhil, F.W.P.J. van den Berkmortel, K. H. Herbschleb, R van Rijn, A.C.J. van Akkooi, Geke A. P. Hospers, J.B.A.G. Haanen, Ellen Kapiteijn, B. Leeneman, Djura Piersma, A.J. ten Tije, A.J.M. van den Eertwegh, M. G. Franken, Maureen J.B. Aarts, J.W.B. de Groot, M van Zeijl, K. J. van der Hoeven, Karijn P M Suijkerbuijk, C.A. Uyl-de Groot, A.A.M. Van der Veldt, Michel W.J.M. Wouters
Publikováno v:
Value in Health. 21:S51
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a963b2e1cc984ffd19eb9977ccd359ef
https://doi.org/10.1016/j.jval.2018.09.302
https://doi.org/10.1016/j.jval.2018.09.302
Publikováno v:
Nederlands tijdschrift voor tandheelkunde. 121(4)
A 72-year-old man, edentulous in the maxilla for 20 years, presented himself at his dentist in 2006 with complaints concerning retention of his upper denture. The placement of implants was only possible if bone augmentation was undertaken; this was d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::b76f2ae16913a2aa7d383258dfcb9655
https://pubmed.ncbi.nlm.nih.gov/24881260
https://pubmed.ncbi.nlm.nih.gov/24881260
Autor:
H M, Blommestein, M G, Franken, S G R, Verelst, M, van Agthoven, P C, Huijgens, C A, Uyl-de Groot
Publikováno v:
The Netherlands journal of medicine. 72(4)
To investigate whether equal access to bortezomib has been achieved under the Dutch policy regulations that guarantee equal access to expensive inpatient drugs.We investigated accessibility to bortezomib treatment at national and regional levels by (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::34086417fcbd413f652cda4e5ab2ad33
https://pubmed.ncbi.nlm.nih.gov/24829184
https://pubmed.ncbi.nlm.nih.gov/24829184
Autor:
J G, Gaultney, M G, Franken, S S, Tan, W K, Redekop, P C, Huijgens, P, Sonneveld, C A, Uyl-de Groot
Publikováno v:
Journal of clinical pharmacy and therapeutics. 38(1)
High costs of novel agents increasingly put pressure on limited healthcare budgets. Demonstration of their real-world costs and cost-effectiveness is often required for reimbursement. However, few published economic evaluations of novel agents for mu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::76861339074bf98fc5be18e220f3c559
https://pubmed.ncbi.nlm.nih.gov/23126374
https://pubmed.ncbi.nlm.nih.gov/23126374